Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. - Wikidata - wikimedia - TriplyDB

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

http://www.wikidata.org/entity/Q36295446

about

Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents Orthopox Viruses: Infections in Humans Inhibition of Poxvirus Gene Expression and Genome Replication by Bisbenzimide Derivatives Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice A cutting-edge view on the current state of antiviral drug development.Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246.Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections Utilizing diversity-oriented synthesis in antimicrobial drug discovery.Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Update on new antivirals under development for the treatment of double-stranded DNA virus infections Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.Therapeutic and prophylactic drugs to treat orthopoxvirus infections Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.Orthopoxvirus targets for the development of new antiviral agents.ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Camelpox: epidemiology, diagnosis and control measures.The search for new therapies for human cytomegalovirus infections.Historical perspectives in the development of antiviral agents against poxviruses Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin.Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.Vaccinia Virus Natural Infections in Brazil: The Good, the Bad, and the Ugly.Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.

P2860

Q24629979-7CF78369-500C-427D-9F0D-2D6145616E5A Q28384852-721B3DEE-5968-43EF-951E-D6025D3C9572 Q28742218-62228323-A4A8-4251-946D-EF7BA215F6BE Q32174436-70760128-ADE4-48CD-9FFE-BF1940B32F8F Q33351233-4D2CAD3C-286D-4275-AE2A-1F912D8A0A5D Q33639966-14BA6D50-DC01-4671-AEA8-5AE267E947FD Q34036018-535E7AD9-01FD-4C6C-BDC3-C7951C8C0AA1 Q34483696-CA9379AF-3165-40FD-92C2-19490E919155 Q35023470-F521FB9A-2247-49D2-A64C-B821A626BFD1 Q35152092-7DB9EE78-CBAC-47EB-B9E8-4F6CE9C2D1F6 Q35260533-6B9AACE8-73E0-43A9-A8DC-F1B3B4156DC4 Q35261304-972A58E3-2B6C-4A32-AD30-F8AD1A206DB9 Q35270714-7F224D8B-BE13-41EE-B59E-5A65478B8704 Q35510383-2FFF6F82-2898-4B43-B967-6C56B3C76292 Q35738585-86CBE64F-94F3-474A-998F-DB20939BD248 Q36130201-57A34A86-8445-4E82-9A43-3AF0B6408D02 Q36185647-7B4242A8-5DD4-47D3-A65C-EA6D9996ED86 Q36486818-F71B820A-DEFE-4A58-8F22-889BAE676FE0 Q36667010-EF72FB6D-2BD8-4F4A-A03E-7F4246B51BC8 Q37009973-2EC24C24-58A1-4C6D-9A3E-31EC1EEC8925 Q37043625-6A1AD94A-7739-491E-8DD0-1AA1154FD1C1 Q37062384-1BD97642-6E5E-446D-9D11-75CBD4A8AA98 Q37072113-354DEDB6-41CD-4758-BD20-F37E75C7DF54 Q37173398-190A0422-5A5D-4A98-BC2F-D46D8E367BCC Q37190669-6E50F06B-9D36-480C-97F6-4AE6EB4E0D86 Q37204210-7563D4F4-214E-45FC-AAD9-58EB1FB1DC13 Q37331541-F03C1E8D-2E8E-4C71-B0DD-2F4B9E6E92F5 Q37401749-6629E8B4-EECC-48CC-811A-48D2DE9FA6FB Q37593480-9901227D-D6DC-4285-91AC-32341683305B Q37800922-6D7ACAB5-322E-46EB-B27A-EFA1B10040BD Q37811458-7F2C2077-E537-4CFF-A613-A43936F3C445 Q38617932-F0061D1A-9259-42A5-B3E6-121A0FA4CAAC Q38694084-A2BD91A1-1A29-4172-BE8E-101D605148A9 Q39046951-C37C607A-4BD3-4B1C-BEFC-F09C03923EAB Q39420959-3DD43FD3-D1BB-4206-9C55-8FB092E0B162 Q39539133-C05CAEAA-2A2A-49CB-AC94-4C8DA0657827 Q39929713-73815B1C-D98E-49AE-9727-945BF693E530 Q42974816-FE02C5AB-B77C-4047-8CFF-29C03AE21120 Q45324824-EE634792-6C0C-4810-B7FA-8BB797F4721C Q45325171-2D1A4545-B797-4EA4-A7FD-0FD8289051C5

P2860

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

http://www.wikidata.org/entity/Q36295446

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@ast

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@en

type

label

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@ast

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@en

prefLabel

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@ast

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@en

P1433

Q36295446-9F77C71E-BD0F-4F49-9BA6-FB9D06A28DE6

P1476

Q36295446-A305D31D-6F45-48E3-819A-4972D73B7C7D

P2093

Q36295446-0664EF28-7F63-43A0-8EDD-394CED348CAA

Q36295446-17898927-7B5D-4F76-A1D5-88606E6FF484

Q36295446-3165514F-D4F3-4786-B836-4605CE1E753E

Q36295446-424CCD66-236E-4DB9-B644-C569EB07B4A3

Q36295446-A756BA06-DCBA-40EA-973E-21E1EE85F8B9

Q36295446-D32A304C-9182-49EF-9AC2-0C9A5712D1B9

Q36295446-E21FD31D-5A22-4CE8-A684-25F2AF24DEB3

P2860

Q36295446-1155CD82-EB7F-4CB6-B32A-DED8A186B584

Q36295446-145B832B-1D61-4FA9-9AC8-61E69ED25740

Q36295446-1985AC35-4CD0-42E3-BDF3-F2803393B1B6

Q36295446-32BF964E-E2BF-4514-97EB-69DA845C91B1

Q36295446-5E9E5213-D8C4-45F3-BB9F-EE6071224367

Q36295446-5F42EB76-E808-49FC-8D78-3D231406F98B

Q36295446-7DBC47FA-72A6-480C-9D3A-08F9BC7679BC

Q36295446-82288AE3-86D6-4BC7-8803-097EACC6EA77

Q36295446-8712CEE0-6DA6-4BFD-928A-DA02684383C7

Q36295446-95FA8614-6669-4190-9819-95C570AC6DDE

P304

Q36295446-8F2810C8-B601-4C4C-B0B6-D60787C2AB44

P31

Q36295446-71885A87-34FF-4DEC-8E6D-A55C23CF22AD

P356

Q36295446-597A4135-4BB8-46BF-B6F7-85A8E87A5817

P407

Q36295446-53440671-6BE5-4871-8E04-0D21461D35EE

P433

Q36295446-8AEDB116-1AB2-4C1D-B6D5-F734B25A9A91

P478

Q36295446-1C372654-9ED8-4AEA-9A87-104CE41337FB

P50

Q36295446-927A7212-3402-47BF-BB7D-8B35F5B238F1

P577

Q36295446-61EA852A-E526-42B8-A8BF-AB53A19F2796

P5875

Q36295446-E85F508A-82A7-4CC0-AF02-6B3646C70FF6

P698

Q36295446-6DAB0659-4408-4D1E-9683-E62876F61B01

P932

Q36295446-7CAC64AB-7771-4619-9F15-E8B2EB82BE54

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

@en

P2093

Alice Robertson

http://www.w3.org/2001/XMLSchema#string

Debra C Quenelle

http://www.w3.org/2001/XMLSchema#string

Dennis E Hruby

http://www.w3.org/2001/XMLSchema#string

Earl R Kern

http://www.w3.org/2001/XMLSchema#string

George R Painter

http://www.w3.org/2001/XMLSchema#string

Kathy A Keith

http://www.w3.org/2001/XMLSchema#string

Mark N Prichard

http://www.w3.org/2001/XMLSchema#string

P2860

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge

Use of Internally Controlled Real-Time Genome Amplification for Detection of Variola Virus and Other Orthopoxviruses Infecting Humans

Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice

Simultaneous real-time PCR detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis.

Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Creation of killer poxvirus could have been predicted

Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.

In vitro activity of potential anti-poxvirus agents.

Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.

Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.

P304

4118-4124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00762-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6116467

http://www.w3.org/2001/XMLSchema#string

P698

17724153

http://www.w3.org/2001/XMLSchema#string

P932

2151443

http://www.w3.org/2001/XMLSchema#string